Opinion|Videos|August 5, 2024
Targeting of HER3: Insights from HERTHENA-Lung01
Helena A. Yu, MD, initiates a discussion on the role of HER3 in the development of resistance to EGFR-targeted therapies. She also examines the HERTHENA-Lung01 study and analyzes the emerging data from this trial.
Advertisement
Episodes in this series
- Please discuss the role of HER3 in the development of resistance to EGFR targeted therapies. (
Manickavasagar, et al. Lung Cancer Mang, 2021 ;Engelman, et al. Science, 2007 )- Describe the rationale for targeting HER3 in patients with EGFR TKI resistance.
- What have data shown with treatment strategies using dual targeting of HER3 and EGFR?
- Please review the rationale and study design for HERTHENA-Lung01 and discuss emerging study data and its implications on the treatment landscape. (
Goto, et al. WCLC 2023. Abstract OA05.03 ;Johnson, et al. ESMO 2023. Abstract 1319MO )- Briefly outline the study design and key endpoints. What are your perceptions around the brain mets data presented at ESMO this past year?
- What are some key takeaways from safety data?
- What implications may these findings have on clinical practice?
Advertisement
Related to this article
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5